Trial Profile

Phase I Dose-escalation Trial of Simmitinib for Patients With Advanced Solid Tumors in Therapeutic Failure

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Simmitinib (Primary)
Indications Breast cancer; Carcinoma; Cholangiocarcinoma; Gastric cancer; Lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions
Sponsors CSPC ZhongQi Pharmaceutical Technology

Most Recent Events

02 Jun 2022 Planned End Date changed from 1 Dec 2021 to 31 Mar 2023.
02 Jun 2022 Planned primary completion date changed from 1 Oct 2021 to 31 Jan 2023.
22 Sep 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com